Boston University School of Medicine, 85 East Concord St, 7th Floor, Boston, MA 02118, USA.
Expert Rev Gastroenterol Hepatol. 2011 Dec;5(6):679-84. doi: 10.1586/egh.11.81.
Inflammatory bowel disease (IBD) is a chronic, disabling condition with increasing prevalence throughout the world. Although the etiology of IBD is not well understood, it is characterized by a disproportionate inflammatory response in the gut that leads to tissue damage and clinical symptoms. Over the past decade, the development of biologic therapies that target the proinflammatory cytokine TNF-α in the inflammatory cascade has markedly revolutionized the treatment of IBD. Adalimumab, one of the three available anti-TNF agents, has been shown to effectively induce and maintain remission in patients with Crohn's disease. More recently, data has been published demonstrating the efficacy of adalimumab in patients with ulcerative colitis.
炎症性肠病（IBD）是一种慢性、致残性疾病，其在全球的患病率呈上升趋势。虽然 IBD 的病因尚不清楚，但它的特征是肠道内出现不成比例的炎症反应，导致组织损伤和临床症状。在过去的十年中，针对炎症级联反应中促炎细胞因子 TNF-α 的生物治疗药物的发展，显著改变了 IBD 的治疗方式。阿达木单抗是三种可用的抗 TNF 药物之一，已被证明可有效诱导并维持克罗恩病患者的缓解。最近，已有数据表明阿达木单抗在溃疡性结肠炎患者中的疗效。
